BRPI0721113A2 - Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios - Google Patents

Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios

Info

Publication number
BRPI0721113A2
BRPI0721113A2 BRPI0721113-9A2A BRPI0721113A BRPI0721113A2 BR PI0721113 A2 BRPI0721113 A2 BR PI0721113A2 BR PI0721113 A BRPI0721113 A BR PI0721113A BR PI0721113 A2 BRPI0721113 A2 BR PI0721113A2
Authority
BR
Brazil
Prior art keywords
compound
represent
independently
treat
conditions
Prior art date
Application number
BRPI0721113-9A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jakob Felding
Simon Feldbaek Nielsen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of BRPI0721113A2 publication Critical patent/BRPI0721113A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0721113-9A2A 2006-12-22 2007-12-21 Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios BRPI0721113A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87168906P 2006-12-22 2006-12-22
US94547007P 2007-06-21 2007-06-21
PCT/DK2007/000564 WO2008077404A1 (en) 2006-12-22 2007-12-21 Substituted acetophenones useful as pde4 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0721113A2 true BRPI0721113A2 (pt) 2014-10-07

Family

ID=39156588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721113-9A2A BRPI0721113A2 (pt) 2006-12-22 2007-12-21 Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios

Country Status (23)

Country Link
US (3) US8148537B2 (enExample)
EP (1) EP2125736B1 (enExample)
JP (1) JP5342451B2 (enExample)
KR (1) KR101507717B1 (enExample)
AT (1) ATE503742T1 (enExample)
AU (1) AU2007336538B2 (enExample)
BR (1) BRPI0721113A2 (enExample)
CA (1) CA2673370C (enExample)
CR (1) CR10877A (enExample)
CY (1) CY1111596T1 (enExample)
DE (1) DE602007013617D1 (enExample)
DK (1) DK2125736T3 (enExample)
GT (1) GT200900172A (enExample)
HR (1) HRP20110464T1 (enExample)
IL (1) IL199383A (enExample)
MX (1) MX2009006593A (enExample)
MY (1) MY146022A (enExample)
NO (1) NO20092372L (enExample)
NZ (1) NZ577863A (enExample)
PL (1) PL2125736T3 (enExample)
PT (1) PT2125736E (enExample)
RU (1) RU2493149C2 (enExample)
WO (1) WO2008077404A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2785253A1 (en) 2009-12-22 2011-06-30 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
EP2515866B1 (en) 2009-12-22 2014-02-19 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
JP5873439B2 (ja) 2009-12-22 2016-03-01 レオ ファーマ アクティーゼルスカブ ビタミンd類似体および溶媒と界面活性剤の混合物を含む皮膚組成物
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
EP2925364A1 (en) * 2012-11-30 2015-10-07 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
WO2014096018A1 (en) * 2012-12-19 2014-06-26 Leo Pharma A/S Methods for the preparation of substituted acetophenones
SI3587400T1 (sl) 2013-10-22 2024-05-31 Chiesi Farmaceutici S.P.A. Postopek za pripravo zaviralca pde4
CN106459081B (zh) 2014-06-23 2019-09-10 利奥制药有限公司 1,3-苯并二氧杂环戊烯杂环化合物的制备方法
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
MX385592B (es) 2015-12-18 2025-03-18 Union Therapeutics As Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
KR101702648B1 (ko) * 2016-05-10 2017-02-03 주식회사 엑티브온 피부 외용제용 보존제, 이를 포함하는 화장료 조성물 및 약학 조성물
CN118344381A (zh) 2017-06-20 2024-07-16 联合疗法公司 用于制备1,3-苯并二氧杂环戊烯杂环化合物的方法
EP3838967A1 (en) 2019-12-16 2021-06-23 Spago Nanomedical AB Immobilization of phenolic compounds
CN117924243B (zh) * 2024-01-16 2025-09-12 沈阳药科大学 一种喹啉衍生物及其药用组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (enExample) * 1992-12-23 1995-11-21 Celltech Ltd
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
JP4172817B2 (ja) * 1995-05-19 2008-10-29 協和醗酵工業株式会社 含酸素複素環化合物
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
WO1998022455A1 (en) * 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
HRP20050905A2 (hr) * 2003-03-17 2006-04-30 Kyowa Hakko Kogyo Co. Terapeutski i/ili preventivni agensi za kronične kožne bolesti
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP1888528A2 (en) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
US8324394B2 (en) 2012-12-04
DE602007013617D1 (de) 2011-05-12
WO2008077404A1 (en) 2008-07-03
AU2007336538A1 (en) 2008-07-03
US20120165539A1 (en) 2012-06-28
GT200900172A (es) 2011-10-05
KR101507717B1 (ko) 2015-04-08
PL2125736T3 (pl) 2011-09-30
JP2010513334A (ja) 2010-04-30
RU2493149C2 (ru) 2013-09-20
PT2125736E (pt) 2011-07-01
NZ577863A (en) 2012-04-27
HK1135392A1 (en) 2010-06-04
CY1111596T1 (el) 2015-10-07
IL199383A (en) 2015-02-26
US20100035908A1 (en) 2010-02-11
CA2673370A1 (en) 2008-07-03
JP5342451B2 (ja) 2013-11-13
EP2125736A1 (en) 2009-12-02
US8148537B2 (en) 2012-04-03
US8497380B2 (en) 2013-07-30
NO20092372L (no) 2009-07-14
HRP20110464T1 (hr) 2011-07-31
EP2125736B1 (en) 2011-03-30
CA2673370C (en) 2015-11-17
MX2009006593A (es) 2009-07-02
AU2007336538B2 (en) 2012-04-05
DK2125736T3 (da) 2011-07-11
CR10877A (es) 2009-07-10
RU2009128191A (ru) 2011-01-27
KR20090098990A (ko) 2009-09-18
US20130012716A1 (en) 2013-01-10
MY146022A (en) 2012-06-15
ATE503742T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
BRPI0721113A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
HUP0303164A2 (hu) Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények
WO2007071632A3 (en) 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
ATE390421T1 (de) Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
EA200700099A1 (ru) Производные пиридина
WO2004074270A3 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AR054799A1 (es) Derivados de oxindol
ECSP034534A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
UY28333A1 (es) Inhibidores de caspasa y sus usos.
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
EA200701780A1 (ru) Противоопухолевое средство
UA96783C2 (ru) Замещенные метилфенилкетоны, пригодные для использования как ингибиторы pde4

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL